



11TH WORLD CONGRESS OF MELANOMA

IN CONJUNCTION WITH

21ST EADO CONGRESS

**APRIL 3-5
2025**

ATHENS

MEGARON ATHENS
INTERNATIONAL
CONFERENCE CENTER



PROGRAM

latest update 07/02/2025

ON-SITE CONGRESS WITH ADDITIONAL VIRTUAL ACCESS
WORLDMELANOMA2025.COM

TABLE OF CONTENTS

Welcome Message	5
Congress at a Glance	6
Congress History	7
Congress Venue	8
Floor Plan MAICC	10
Congress Faculty	12
Additional Speaker	16
Call for Abstracts	19
General Information from A-Z	21
Scientific Program at a Glance	26
> April 3 rd , 2025	26
> April 4 th , 2025	30
> April 5 th , 2025	34
Scientific Program	38
> April 3 rd , 2025	38
> April 4 th , 2025	48
> April 5 th , 2025	58
Satellite Symposia Program at a Glance	68
Satellite Symposia Program	70
> April 3 rd , 2025	70
> April 4 th , 2025	72
> April 5 th , 2025	74
Sponsors and Exhibitors	76



IMPORTANT DEADLINES

- **January 15th, 2025:**
Early registration fee deadline
- **January 31st, 2025:**
Start of late-breaking & trials in progress abstract submission
- **February 6th, 2025:**
Deadline for late-breaking & trials in progress abstract submission (6:00 pm CET)
- **February 13th, 2025:**
Notification for late-breaking & trials in progress abstracts
- **March 3rd, 2025:**
Poster upload deadline
- **October 15th, 2025:**
End of On-Demand service



**11TH WORLD CONGRESS
OF MELANOMA**
IN CONJUNCTION WITH
21ST EADO CONGRESS

CONGRESS PRESIDENTS



Prof. Axel Hauschild
Kiel, Germany



Prof. Claus Garbe
Tuebingen, Germany



Prof. Alexander Stratigos
Athens, Greece

WELCOME MESSAGE

Dear colleagues and friends,

We have the great honour and pleasure to invite you to join us for the **11th World Congress of Melanoma in conjunction with the 21st EADO Congress** which will be held under the auspices of two renown authorities in the field of continuous medical education, the Melanoma World Society (MWS) and European Association of Dermato-Oncology (EADO).

The World Congress of Melanoma has always been a unique forum of exchange between physicians, scientists, nurses and students. It constitutes a lively exchange of clinical experiences, research work and clinical trial output among experts from all continents reflecting the enormous progress in the field of melanoma and skin cancer. The congress also offers a great opportunity for young colleagues to interact with distinguished faculty, discuss with industry partners and communicate with representatives of patient organizations, creating a formidable learning environment. The 11th World Congress of Melanoma & 21st EADO Congress will be no exception to the rich heritage, reputation and influence of the previous World Congresses.

From a scientific perspective, the program of the conference will provide a comprehensive overview of the most recent advances in melanoma and cutaneous oncology. A variety of plenary lectures, interactive symposia, and workshops will cover the field of **melanoma as well as squamous cell carcinoma, Merkel cell carcinoma, basal cell carcinoma, actinic keratosis, cutaneous sarcomas, adnexal tumors and cutaneous T- and B-cell lymphomas**. The entire spectrum of each disease will be presented including **epidemiology, prevention and early detection, diagnosis and staging, surgical and radiotherapy and systemic and intralesional therapies**. Certain unique elements will be introduced such as special **advocacy sessions** with the participation of invited policymakers, public health professionals and patient organizations. A series of **“interdisciplinary tumor board”** sessions will provide a continuous stream of presentations of interesting or challenging cases with a specific teaching point presented by residents and younger colleagues.

“Socratic dialogues” will also take place in small groups comprised of selected young colleagues from different countries who will be mentored by world-famous experts. Aspired by examples from ancient Greek heritage, the 11th World Congress of Melanoma & 21st EADO Congress will focus on young colleagues, not only serving as a platform of exchanging knowledge but also aiming to a deeply influential effect in their career paths.

Most importantly, the conference will be an opportunity to celebrate the therapeutic milestones achieved in the battle against skin cancer. The meeting will honor the remarkable collective achievements in the field and, through its proceedings, will define the work ahead to the ultimate goal of melanoma cure.

The unique surroundings of the cultural city of Athens and the springtime environment will contribute to what we expect will be a landmark event.

Looking forward to welcoming you in Athens 2025!

CONGRESS AT A GLANCE

Congress Format

On-site congress with additional virtual access

Congress Presidents

Axel Hauschild, Kiel, Germany

Claus Garbe, Tuebingen, Germany

Alexander Stratigos, Athens, Greece

Steering Committee

Paolo Ascierto, Naples, Italy

Jeffrey Gershewald, Houston, USA

Helen Gogas, Athens, Greece

Jun Guo, Beijing, China

Allan C. Halpern, New York, USA

Aimilios Lallas, Thessaloniki, Greece

Georgina Long, Sydney, Australia

Paul Lorigan, Manchester, United Kingdom

Olivier Michielin, Lausanne, Switzerland

Chrysalyne Schmults, Boston, USA

Richard Scolyer, Sydney, Australia

Alexander van Akkooi, Sydney, Australia

Alberto Wainstein, Belo Horizonte, Brazil

Dagmar Whitaker, Cape Town, South Africa

Expected Number of Participants

2,000

Congress Language

English

Congress Venue

Megaron Athens International

Conference Centre

Vas. Sofias & Kokkali

115 21 Athens, Greece

<https://www.megaron.gr/en/>

international-conference-centre/

Congress Website

<https://worldmelanoma2025.com>

Congress Organizer

MEDCONCEPT 

MedConcept GmbH

Friedenstr. 58

15366 Neuenhagen bei Berlin

Germany

Phone: +49 (0) 334242689-30

E-Mail: wcm2025@medconcept.org



- 1985** — Venice, Italy
- 1989** — Venice, Italy
- 1993** — Venice, Italy
- 1997** — Sydney, Australia
- 2001** — Venice, Italy
- 2005** — Vancouver, Canada
- 2009** — Vienna, Austria
- 2013** — Hamburg, Germany
- 2017** — Brisbane, Australia
- 2021** — Virtual Congress
- 2025** — Athens, Greece
- 2029** — Barcelona, Spain



- 2001** — Vienna, Austria
- 2003** — Marseille, France
- 2006** — Rome, Italy
- 2008** — Marseille, France
- 2009** — Vienna, Austria
- 2010** — Athens, Greece
- 2011** — Nantes, France
- 2012** — Barcelona, Spain
- 2013** — Hamburg, Germany
- 2014** — Vilnius, Lithuania
- 2015** — Marseille, France
- 2016** — Vienna, Austria
- 2017** — Athens, Greece
- 2018** — Barcelona, Spain
- 2019** — Paris, France
- 2020** — Virtual Congress
- 2021** — Virtual Congress
- 2022** — Seville, Spain
- 2023** — Rome, Italy
- 2024** — Paris, France
- 2025** — Athens, Greece
- 2026** — Prague, Czech Republic
- 2027** — Vienna, Austria
- 2028** — Maastricht, The Netherlands

CONGRESS HISTORY

World Congresses of Melanoma

In the 1970s, the global melanoma community established a worldwide organization within the WHO, the WHO Melanoma Group. This group initiated a series of international studies, especially in melanoma surgery, that set standards for safety margins in primary melanoma excision and for lymph node surgery. The WHO Melanoma Group also initiated the first World Congress of Melanoma in 1985, which was then held every 4 years. The WHO Melanoma Group held its last meeting at the World Congress of Melanoma 2005 in Vancouver. After that, the Group dissolved because the WHO no longer supported their work.

This is the reason why former members of the WHO Melanoma Group and other worldwide known melanoma experts came together at the World Congress of Melanoma 2013 in Hamburg and founded the Melanoma World Society. At that time, this society set itself the objective of the WHO's previous commitments to the melanoma group, in particular the Organization of the World Congress and other educational congresses on the topic of melanoma. Other goals include supporting global policy development and supporting clinical and scientific research in the world.

EADO Congress

The EADO (European Association of Dermato-Oncology) is an independent non-profit organization dedicated to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. One mission of the EADO is to support and organise meetings dedicated to the presentation of new research findings, exchange of information and education for its members in the field of dermato-oncology. The first EADO Congress was held 2001 in Vienna, Austria.

11TH WORLD CONGRESS OF MELANOMA IN CONJUNCTION WITH 21ST EADO CONGRESS



CONGRESS VENUE

The Megaron Athens International Conference Centre (MAICC) is one of the most modern conference venues in Europe, offering flexible spaces, stunning aesthetics and state-of-the-art technology. Located in the centre of Athens, MAICC has a total offering of 143,000 square metres and a choice of 18 meeting spaces, combined with expansive exhibition and foyer areas.

In addition, the venue offers 750 parking spaces and is located on a direct metro line to the Eleftherios Venizelos International Airport, journey time 35 minutes.







Airport

Athens International Airport "Eleftherios Venizelos", commonly initialised as AIA, is located 33km away from Athens city and the congress venue Megaron Athens International Conference Centre (MAICC).



FLOOR PLAN MAICC





CONGRESS FACULTY

A

Adams David
Cambridge, United Kingdom

Agarwala Sanjiv
Philadelphia, USA

Alcalay Joseph
Tel-Aviv, Israel

Amaral Teresa
Tuebingen, Germany

Apalla Zoe
Thessaloniki, Greece

Arance Ana
Barcelona, Spain

Arenberger Petr
Prague, Czech, Republic

Argenziano Giuseppe
Naples, Italy

Ascierto Paolo
Naples, Italy

B

Bafaloukos Dimitris
Athens, Greece

Bataille Veronique
London, United Kingdom

Bechrakis Nikolaos
Essen, Germany

Becker Jürgen
Essen, Germany

Berking Carola
Erlangen, Germany

Bhatia Shailender
Seattle, USA

Blank Christian
Amsterdam, The Netherlands

Bosisio Francesca Maria
Leuven, Belgium

Bylaite-Bucinskiene Matilda
Vilnius, Lithuania

D

Davies Michael
Houston, USA

Del Marmol Veronique
Brussels, Belgium

Dessinioti Clio
Athens, Greece

Dirschka Thomas
Wuppertal, Germany

Dréno Brigitte
Nantes, France

Dummer Reinhard
Zurich, Switzerland

E

Eggermont Alexander
Utrecht, The Netherlands

Eigentler Thomas
Berlin, Germany

F

Fargnoli Maria Concetta
Rome, Italy

Forschner Andrea
Tuebingen, Germany

Forsea Ana-Maria
Bucharest, Romania

G

Gajewski Thomas
Chicago, USA

Garbe Claus
Tuebingen, Germany

Gebhardt Christoffer
Hamburg, Germany

Gershenwald Jeffrey
Houston, USA

Geusau Alexandra
Vienna, Austria

Gogas Helen
Athens, Greece

Grabbe Stephan
Mainz, Germany

Griewank Klaus
Essen, Germany

Guenova Emmanuella
Linz, Austria

Guo Jun
Beijing, China

Gutzmer Ralf
Minden, Germany

H

Halpern Allan C.
New York, USA

Hamid Omid
Los Angeles, USA

Harwood Catherine
London, United Kingdom

Hassel Jessica
Heidelberg, Germany

Hauschild Axel
Kiel, Germany

Heppt Markus
Erlangen, Germany

Höller Christoph
Vienna, Austria

J

John Swen-Malte
Osnabrueck, Germany

K

Kalirai Helen
Liverpool, United Kingdom

Kandolf Lidija
Belgrade, Serbia

Kaufmann Roland
Frankfurt, Germany

Kelleners-Smeets Nicole
Maastricht, The Netherlands

Kinsler Veronica
London, United Kingdom

Kittler Harald
Vienna, Austria

Krasagakis Konstantinos
Heraklion, Greece

L

Lallas Aimilios
Thessaloniki, Greece

Landi Maria Teresa
Bathesda, USA

Lebbé Céleste
Paris, France

Leiter-Stöppke Ulrike
Tuebingen, Germany

Lianidou Evi
Athens, Greece

Liopyris Konstantinos
Athens, Greece

Livingstone Elisabeth
Essen, Germany

Long Georgina
Sydney, Australia

Longo Caterina
Reggio Emilia, Italy

Lorigan Paul
Manchester, United Kingdom

Lugowska Iwona
Warsaw, Poland

M

Malveyh Josep
Barcelona, Spain

Mandalá Mario
Perugia, Italy

Markel Gal
Tel Aviv, Israel

McArthur Grant
Melbourne, Australia

Michielin Olivier
Geneva, Switzerland

Mijuskovic Zeljko
Belgrade, Serbia

Mohr Peter
Buxtehude, Germany

Moreno-Ramirez David
Seville, Spain

Munhoz Rodrigo R.
Sao Paulo, Brazil

N

Nakamura Yasuhiro
Saitama, Japan

Nathan Paul
London, United Kingdom

Neyns Bart
Brussels, Belgium

Nikolaou Viky
Athens, Greece

O

Oláh Judit
Szeged, Hungary

Ortiz Pablo
Madrid, Spain

P

Patel Sapna
Denver, USA

Patton Liz
Edinburgh, United Kingdom

Pellacani Giovanni
Modena, Italy

Petrella Teresa
Toronto, Canada

Plasmeijer Elsemieke
Amsterdam, The Netherlands

Postow Michael
New York, USA

Puig Susana
Barcelona, Spain

Q

Quaglino Pietro
Turin, Italy

R

Robert Caroline
Paris, France

Ross Merrick I.
Houston, USA

Rutkowski Piotr
Warsaw, Poland

Ryll Bettina
Uppsala, Sweden

S

Saiag Philippe
Boulogne, Billancourt France

Schadendorf Dirk
Essen, Germany

Schilling Bastian
Frankfurt, Germany

Schmults Chrysalyne
Boston, USA

Scolyer Richard
Sydney, Australia

Shaw Heather
London, United Kingdom

Sibaud Vincent
Toulouse, France

Sekulic Aleksandar
Phoenix, USA

Situm Mirna
Zagreb, Croatia

Sondak Vernon
Tampa, USA

Stefanaki Irene
Athens, Greece

Stockfleth Eggert
Bochum, Germany

Stratigos Alexander
Athens, Greece

Sullivan Ryan
Boston, USA

Svane Inge Marie
Copenhagen, Denmark

T

Tagliaferri Luca
Rome, Italy

Tawbi Hussein
Houston, USA

Thomas Luc
Lyon, France

Theocharis Sotirios
Athens, Greece

Trakatelli Myrto
Thessaloniki, Greece

U

Ugurel Selma
Essen, Germany

V

van Akkooi Alexander
Sydney, Australia

Venables Zoe
Norwich, United Kingdom

Vieira Ricardo
Coimbra, Portugal

W

Wainstein Alberto
Belo Horizonte, Brazil

Wargo Jennifer
Houston USA

Weichenthal Michael
Kiel, Germany

Welzel Julia
Augsburg, Germany

Whitaker Dagmar
Cape Town, South Africa

Whiteman David
Brisbane, Australia

Winkler Julia
Heidelberg, Germany

Z

Zalaudek Iris
Trieste, Italy

Zimmer Lisa
Essen, Germany

Zitvogel Laurence
Paris, France

ADDITIONAL SPEAKER

A

Akay Bengü Nisa
Ankara, Turkey

Arenbergerova Monika
Prague, Czech Republic

Assaf Chalid
Krefeld, Germany

Astratinei Violeta
Amsterdam, The Netherlands

B

Basset-Seguin Nicole
Paris, France

Borch Troels Holz
Copenhagen, Denmark

Brown Kevin
Bathesda, USA

C

Cascone Tina
Houston, USA

Cust Anne
Sydney, Australia

D

Daud Adil
San Francisco, USA

de la Fourchadiere Arnaud
Lyon, France

Di Nardo Lucia
L'Aquila, Italy

Dimitriou Florentia
Houston, USA

E

Elder David
Philadelphia, USA

F

Ferrandiz-Pulido Carla
Barcelona, Spain

Fisher David E.
Boston, USA

Fukushima Satoshi
Kumamoto, Japan

G

Gammage Payam
Glasgow, Scotland

Guild Samantha
Richmond, USA

Gyulai Rolland
Szeged, Hungary

H

Heimann Heinrich
Liverpool, United Kingdom

Helgadottir Hildur
Stockholm, Sweden

I

Ito Takamich
Fukuoka, Japan

J

Jönsson Göran
Lund, Sweden

Jouary Thomas
Bordeaux, France

K

Kaminski Katharina
Essen, Germany

Kölblinger Peter
Salzburg, Austria

L

Landi Maria Teresa
Bethesda, USA

Lazaridou Elizabeth
Thessaloniki, Greece

Lenneman Carrie
Birmingham, USA

Lian Bin
Beijing, China

Lo Roger
Los Angeles, USA

Lodde Georg
Essen, Germany

M

Maubec Eve
Bobigny, France

Meier Friedegund
Dresden, Germany

Migden Michael
Houston, USA

Moscarella Elvira
Reggio Emilia, Italy

Mosterd Klara
Maastricht, Netherlands

N

Nagore Eduardo
Valencia, Spain

P

Papadavid Evangelia
Athens, Greece

Patel Vishal
Washington, USA

Pellegrini Cristina
L'Aquila, Italy

Perez Javiera
Barcelona, Spain

Poulikakos Poulikos
New York, USA

Proby Charlotte
Dundee, United Kingdom

R

Rembielak Agata
Manchester, United Kingdom

Robert Caroline
Paris, France

Rossi Elena
Modena, Italy

S

Scarisbrick Julia
Birmingham, United Kingdom

Scaini Maria Chiara
Padova, Italy

Shain Alan Hunter
San Francisco, USA

Smalley Inna
Tampa, USA

Soerjomataram Isabelle
Lyon, France

Soyer Peter
Brisbane, Australia

Starrace Michela Valeria
Bologna, Italy

Stein Deutsch Julia
Baltimore, USA

Suijkerbuijk Karijn
Utrecht, The Netherlands

Suppa Mariano
Brussels, Belgium

T

Tasdogan Alpaslan
Essen, Germany

Taube Janis
Baltimore, USA

U

Uhara Hisashi
Sapporo, Japan

V

Visser Willie
Stellenbosch, South Africa

Vossaert Katrien
Gent, Belgium

W

Weinlich Georg
Innsbruck, Austria

Wilmott James
Sydney, Australia

Wojcieszek Piotr
Gliwice, Poland

Wong Michael K.
Houston, USA

Z

Zaremba Anne
Essen, Germany

CALL FOR ABSTRACTS

Abstract Submission Deadline: January 15, 2025 (6:00 pm CET)

All those interested in presenting abstracts at the 11th World Congress of Melanoma & 21st EADO Congress are invited to submit their work to the Program Committee for review. Selected abstracts will be chosen for an oral presentation during the free communications sessions or as e-posters for virtual consultation. The acceptance of an abstract does not include the congress registration. Authors must be registered for the congress until February 14, 2025 in order to present their work.

Abstract Topics

- Actinic keratoses
- Basal cell carcinoma
- Cutaneous sarcoma
- Cutaneous T- and B-cell lymphoma
- Melanoma – Epidemiology and diagnostics
- Melanoma – Experimental and translational studies
- Melanoma – Immune checkpoint inhibitor (ICI) therapy
- Melanoma – Surgery
- Melanoma – Systemic therapy other than ICI therapy
- Merkel cell carcinoma
- Rare tumors
- Squamous cell carcinoma

Abstract Guidelines

- Abstracts may be **submitted online via the congress website**. Abstracts submitted by e-mail will not be accepted.
- Abstracts must be received by the **announced deadline**. Abstracts received after the deadline will not be considered.
- The **title** should be as brief as possible but long enough to clearly indicate the nature of the study. Abbreviations must not be used in the title. The title should not be written entirely in capital letters (e.g. NOT LIKE THIS).
- Please indicate the **topic** from the abstract topics list and your preferred type of presentation (oral or poster). The Committee will endeavor to schedule abstracts according to authors' preferences but reserves the right to decide on the final form of presentation.
- **Encore abstracts** will be accepted unless they have been published in scientific journals.
- Please structure the abstract as follows:
 - **Introduction & Objectives:** Describe the background and the purpose of the study
 - **Materials & Methods:** Describe the material and methods used to design the study
 - **Results:** Describe your results in a logical sequence
 - **Conclusions:** Emphasise new and important aspects of the study and conclusions that are drawn from them

IMPORTANT DEADLINES



➤➤➤ **January 15, 2025:**
Deadline for abstract submission (6:00pm CET)

➤➤➤ **January 31, 2025:**
Start of late-breaking & trials in progress abstract submission

➤➤➤ **February 6, 2025:**
Deadline for late-breaking & trials in progress abstract submission (6:00pm CET)

➤➤➤ **February 13, 2025:**
Notification of acceptance of abstracts including late-breaking & trials in progress abstracts

➤➤➤ **March 3, 2025:**
Poster Upload Deadline

- The text shall not exceed 350 words including spaces (excluding title, authors bibliography and key words). The submission program will automatically calculate the number of characters in your abstract and will not allow submissions that exceed the maximum number of characters.
- It is acceptable to include up to two **tables, graphics, or images (jpg, jpeg, png, gif format, maximum size 2 MB in total)** as part of the abstract.
- All abstracts must be submitted and presented in clear **English** with accurate grammar and spelling of a quality suitable for publication. Abstracts will not be edited by the Congress Secretariat prior to publication, therefore please check the grammar and spelling carefully.
- Please use generic names. **The use of commercial drug names, brands and registered trademarks are strictly prohibited.** Drugs should be referred to by the active substance or pharmacological designation.
- No mention of pharmaceutical company names should be included in the abstract.

Patient Privacy/Clinical Photography

Photographs should at all times protect the privacy and identity of the subject. Eyes should be blacked out. The source of the photographs must also be declared if not the property of the presenter. This is to prevent the use of photographic material without permission.

Oral Presentations

Selected abstracts will be chosen for an oral presentation during the free communications sessions. The presenting author does not have to be the first author.

Poster Presentation

Abstracts selected for poster will be presented as printed posters during the congress. Further information will be provided prior to the congress.

Publication

All accepted abstracts will be published in the digital Book of Abstracts which will be available for download on the congress website from March 15, 2025 onwards. The Book of Abstract will also be published on the EADO website under Events & Training/EADO Congress after the conference.

Registration

Please note that the acceptance of an abstract does not include the congress registration. The presenting author must be a registered participant, otherwise the abstract will not be reviewed and waived from the program.

Abstract Awards

Further information will be available soon.

GENERAL INFORMATION FROM A-Z

Accommodation

Further information will be available soon.

Badges

The name badge is the official congress identification document. Please wear your badge at all times in order to gain entry into the session rooms and exhibition area. Admission to the congress area will not be permitted without badge identification. Kindly note that for the reprinting of lost or forgotten badges, an administrative fee of 20 Euro will be charged.

Cancellation Policy

Cancellations must be received in writing to registrations@worldmelanoma2025.com by February 14, 2025. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled/amended registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to registrations@worldmelanoma2025.com.

Certificate of Attendance

For the download of the certificate of attendance and the CME certificate you will receive an email with a link for download after the congress. Before downloading your certificate, you must answer the official EACCME questionnaire.

Cloakroom and Luggage

Further information will be available soon.

CME Credits

In order to receive the CME points, please have your name badge scanned daily. This serves to record your attendance and the corresponding allocation of the CME points. You will receive your certificates of attendance by e-mail after the event. (Please note that you will need to fill in the official EACCME questionnaire, which you will also receive by e-mail after the congress).

Congress Bag

Congress bags can be picked up at the registration desk. Each bag contains a copy of the Congress Program at a Glance and other useful information.

Congress Program

Please note that there will be no printed program provided on-site for sustainability reasons. You may find the printed Program at a Glance in your congress bag. The full program can be viewed via the congress app or can be downloaded as a pdf from the congress website. All registered delegates will receive further information by email shortly before the congress. Delegates may also scan the QR code available at the Registration Desk using their iPhone or Android.



CONGRESS ORGANIZATION

MEDCONCEPT 

Gesellschaft für medizinische
Projekte mbH
Friedenstr. 58
15366 Neuenhagen bei Berlin
Germany

Phone +49 (0)3342 - 42 68 930

E-Mail: wcm2025@medconcept.org
www.medconcept.org

Congress Venue

Megaron Athens International Conference Centre
Vas. Sofias & Kokkali
115 21 Athens, Greece
<https://www.megaron.gr/en/international-conference-centre/>



Exhibition

A commercial exhibition will run during the congress. Visit the onsite industrial exhibition to get in touch with exhibitors, colleagues, collaborators and friends. As soon as available, you can view the booth plan via the congress website <https://worldmelanoma2025.com> (from the end of 2024).

Exhibition Opening Hours

Further information will be available soon.

First Aid

In case of emergency, please go to the First Aid room.
The Greek number for the ambulance service is 166.

Insurance

The organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect of health and travel insurance.

Language and Translation

The official language of the meeting is English. Simultaneous translation will not be provided.

Liability Disclaimer

In the unlikely occurrence that the congress must be cancelled or postponed due to circumstances beyond the control of the organizers (natural disasters, political, social or economic events or other unforeseen events beyond control), the organizers cannot be held liable for any costs incurred by the event attendee. The organizer will record images during the event. By virtue of attendance, attendees agree to the organizer's usage of these recordings on the website and for marketing.

Lost & Found

Please hand in all found items at the registration desk. A lost and found box will be provided there.

Lunches and Refreshments

Coffee breaks and lunch will be served in the exhibition area on the ground floor. It is not allowed to bring food into the Amphitheatre/Meeting Rooms.

Parking Facilities

The venue offers 600 parking spaces which are open daily from 06:00am–02:00am.

Program Changes

The organizer reserves the right to make changes to the event program at short notice if necessary. This does not result in any reimbursement claims. Program changes will be announced during the congress.

Questions to Speakers

Questions can be asked online via the congress app. In addition to that wireless microphones will be available during the discussion period in all sessions. Delegates wishing to participate in the discussion periods should make their way to the nearest microphone placed in the aisles.

Registration

Registration is only possible by using the online portal on the congress website. Further information will follow soon. For group bookings, there will be a group booking portal on the congress website.

Category/Fee	Regular & Onsite Fee On-Site Attendance from January 16 th , 2025	Early Bird Fee On-Site Attendance until January 15 th , 2025	Virtual Attendance
Full Delegate/ Non-EADO Member	800 €	700 €	700 €
EADO Member	700 €	600 €	600 €
"Resident/Trainee/Medical Fellow Scientist/Allied Health Professional/Nurse*"	500 €	400 €	400 €
Student*	250 €	200 €	200 €
Day Tickets**	350 €	250 €	–

* The resident/student registration rate will be granted only after receipt of proof. The written proof of status (e.g. letter signed by the head of department confirming the status of the applicant/copy of student ID card) can be uploaded online during the registration process.

** Virtual participation and the on-demand service are not included in the day tickets.

Method of payment:

Only credit cards (Visa, MasterCard, American Express and PayPal) will be accepted. Bank transfers are only possible in exceptional cases for group bookings/hospitals. Please note that in payments by bank transfers, the bank charges must be paid by the delegate.

On-site registration fee covers:

- › Admission to on-site & virtual scientific sessions and satellite symposia
- › Admission to the on-site & virtual industrial exhibition
- › On-site coffee breaks
- › Congress bag
- › Opening ceremony
- › Certificate of attendance
- › Book of abstracts
- › Login to the on-demand area (session files will be available until October 15, 2025)

Virtual registration fee covers:

- › Admission to virtual streaming of scientific sessions and satellite symposia
- › Admission to virtual industrial exhibition
- › Virtual opening ceremony

- › Certificate of attendance
- › Book of abstracts
- › Login to the on-demand area (session files will be available until October 15, 2025)

Registration Desk

The registration desk is situated on the ground floor.
Further information will be available soon.

Smoking

Smoking is strictly forbidden within the congress center.

Social Networks

Stay tuned and connected and follow the conference on Instagram and Facebook.



@worldmelanoma2025, @eado_melanoma, @melanomaworldsocietymwus

Speaker Preview Room

A Speakers' Preview Room is provided for all speakers. All presentations must be downloaded in the Speakers' Preview Room beforehand, as the presentations will be sent directly to the meeting room through the internal computer network.

The following facilities will be provided in the room: computers (Windows operating system) to review, alter and upload the presentations to the server and support by technical staff.

The presentations should be handed into the Speakers' Preview Room **at least two hours before the session**. Speakers with a presentation during the first time slot of the morning are kindly asked to hand in their presentation the day before. All speakers will be able to find their presentations easily on the preview monitor on the lectern in the corresponding session room.

Sustainability

Sustainability is more important today than ever before. We are working internally on increasing our sustainability efforts and would like to encourage all involved in the 11th World Congress of Melanoma in conjunction with the 21st EADO Congress to minimize their environmental and social impacts. Go Green – Acting today for tomorrow!

Ways to get involved:

- › Travel by train/by carbon offsetting your flights to Athens and encourage your colleagues to do the same
- › Use the recycling bins provided on-site
- › Recycle your name-badge in the bin provided at the registration desk
- › Recycle all brochures and promotional items not needed in the bin provided within the industrial exhibition
- › Use the public transportation system in Athens.

Welcome Reception

All registered delegates are invited to join the welcome reception on Thursday, April 3, 2025 from 18:00–20:00 which will be held within the exhibition area. The Welcome Reception is open to all registered delegates, sponsors and exhibitors.

Time Zone

Athens is in the Eastern European Time Zone which is 2 hour ahead of Greenwich Mean Time (GMT +2). Like most states in Europe, Athens observes daylight saving (summer time). On Sunday, March 30, 2025 time will be shifted forward by 1 hour (GMT+3).

Weather

In April, the temperatures during the day in Athens range between 12 °C and 20 °C. However, the daily average temperature for Athens during April is around 18 °C.

Wi-Fi

Free Wi-fi will be available within the congress area. Further information will be available soon.



SCIENTIFIC PROGRAM AT A GLANCE

THURSDAY, APRIL 3RD, 2025

	Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
08:00	Opening Ceremony		
09:00	SYMPOSIUM SY01 Controversies – Skin cancer screening should be abandoned!	SYMPOSIUM SY02 Dermoscopy 1: Total body photography, digital dermoscopy and scanners: indications and procedures	SYMPOSIUM SY03 Prognostic and predictive biomarkers in melanoma
10:00	SYMPOSIUM SY06 Controversies – Does melanoma follow-up contribute to overall survival improvement?	SATELLITE SYMPOSIUM SAT01 Gold Sponsor	SYMPOSIUM SY07 Melanoma guidelines around the world
	Break		
11:00	KEYNOTE LECTURE KEY01 Skin cancer epidemic: is there light at the end of the tunnel?		
	KEYNOTE LECTURE KEY02 The journey from melanocytes to melanoma		
12:00	SATELLITE SYMPOSIUM SAT02 Platinum Sponsor		
13:00	Break		
14:00			

Skalkotas Hall 380 seats/Level -1	M3 180 seats/Level -1	M2 150 seats/Level -1	
			08:00
SYMPOSIUM SY04 Squamous cell carcinoma: epidemiology and management	SYMPOSIUM SY05 Merkel cell carcinoma: epidemiology, surgery and radiology		09:00
SYMPOSIUM SY08 Intralesional therapies of skin cancer	SYMPOSIUM SY09 Liquid biopsy as a decision maker in melanoma?		10:00
			11:00
			12:00
			13:00
			14:00

THURSDAY, APRIL 3RD, 2025

	Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
14:00	SYMPOSIUM SY10 Melanoma classifications: past, present and future	SATELLITE SYMPOSIUM SAT03 Gold Sponsor	SYMPOSIUM SY11 Treatment of cutaneous lymphomas: what's coming from the pipeline?
15:00	SYMPOSIUM SY15 Neoadjuvant treatment of melanoma	SYMPOSIUM SY16 Basal cell carcinoma: epidemiology and management	SATELLITE SYMPOSIUM SAT04 Silver Sponsor
			SATELLITE SYMPOSIUM SAT05 Silver Sponsor
16:00	Break		
17:00	SYMPOSIUM SY19 Artificial Intelligence in dermato-oncology	SYMPOSIUM SY20 Registries for real world treatment data and outcome research	SATELLITE SYMPOSIUM SAT06 Further Sponsor
			SATELLITE SYMPOSIUM SAT07 Further Sponsor
18:00			
19:00	Welcome Reception		
20:00			

Skalkotas Hall 380 seats/Level -1	M3 180 seats/Level -1	M2 150 seats/Level -1	
SYMPOSIUM SY12 Adoptive T-Cell transfer (TILs) for advanced melanomas	SYMPOSIUM SY13 Interdisciplinary tumor board: challenging skin cancer cases I	SYMPOSIUM SY14 Overdiagnosis of melanoma: a real problem?	14:00
SYMPOSIUM SY17 Immunotherapy of Merkel cell carcinoma	SYMPOSIUM SY18 Primary ocular melanoma: genetics, clinical appearance and treatment	FREE COMMUNICATION I	15:00
			16:00
SYMPOSIUM SY21 Memorial Symposium for Jeff Weber Drug resistance to immune check- point inhibition	SYMPOSIUM SY22 Skin Care in Organ Transplant Patients Europe (SCOPE)	FREE COMMUNICATION II	17:00
			18:00
			19:00
			20:00

SCIENTIFIC PROGRAM AT A GLANCE

FRIDAY, APRIL 4TH, 2025

	Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
07:00			
08:00			
	Break		
09:00	SYMPOSIUM SY23 Melanoma research	SYMPOSIUM SY24 Congenital nevi: risk and management	SATELLITE SYMPOSIUM SAT08 Silver Sponsor
10:00	SYMPOSIUM SY27 Controversies – Is there a future for sentinel node biopsy?	SATELLITE SYMPOSIUM SAT09 Gold Sponsor	SYMPOSIUM SY28 Drug resistance to targeted therapies
11:00	Break		
12:00	SYMPOSIUM SY31 Adjuvant treatment of melanoma	SYMPOSIUM SY32 Management of brain metastasis	SATELLITE SYMPOSIUM SAT10 Further Sponsor
13:00	SATELLITE SYMPOSIUM SAT11 Platinum Sponsor		

Skalkotas Hall 380 seats/Level -1	M3 180 seats/Level -1	M2 150 seats/Level -1	07:00
SOCRATES' DIALOGUES I: AN INTERACTIVE MORNING SESSION Treatment refractory stage IV melanomas: what do I do?	SOCRATES' DIALOGUES II: AN INTERACTIVE MORNING SESSION Women in dermato-oncology	SOCRATES' DIALOGUES III: AN INTERACTIVE MORNING SESSION The role of microbiome for immunotherapies	08:00
SYMPOSIUM SY25 Management of mucosal melanoma	SYMPOSIUM SY26 Microbiome in cancer: more than gut feelings?	FREE COMMUNICATION III	09:00
SYMPOSIUM SY29 Molecular tumor board for skin cancers	SYMPOSIUM SY30 Treatment of field cancerization including actinic cheilitis		10:00
SYMPOSIUM SY33 Radiotherapy for melanoma and other skin cancers: where are we now?	SYMPOSIUM SY34 Surgical pearls in the treatment of skin cancer	SYMPOSIUM SY35 Rare skin tumors (adnexal, sebaceous, DFSP)	11:00
			12:00
			13:00

FRIDAY, APRIL 4TH, 2025

	Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
13:00	Break		
14:00	KEYNOTE LECTURE KEY03 Diagnostic tools for skin cancer detection beyond dermoscopy		
15:00	KEYNOTE LECTURE KEY04 New diagnostics, prognostic biomarkers and systemic therapy strategies sharply reduce the need for surgery in melanoma		
16:00	SYMPOSIUM SY36 Immune checkpoint inhibition for non-melanoma skin cancer	SYMPOSIUM SY37 High-risk melanocytic nevi: are they existing, and how to define what to do?	SATELLITE SYMPOSIUM SAT12 Further Sponsor
17:00	SYMPOSIUM SY41 Global epidemiologic trends and survival in skin cancer	SYMPOSIUM SY42 Immunotherapies of metastatic ocular melanoma in first- and second line	SATELLITE SYMPOSIUM SAT13 Further Sponsor
18:00			
19:00			

Skalkotas Hall 380 seats/Level -1	M3 180 seats/Level -1	M2 150 seats/Level -1	
			13:00
			14:00
			15:00
SYMPOSIUM SY38 Drug access across the world: approval is not reimbursement!	SYMPOSIUM SY39 Cutaneous sarcomas: diagnosis and treatment	SYMPOSIUM SY40 Mohs micrographic surgery and skin cancer management	16:00
SYMPOSIUM SY43 Occupational skin cancer: The sleeping giant (4 th Multi-stakeholder summit)	SYMPOSIUM SY44 Skin cancer on colored skin: clinical appearance and treatment	FREE COMMUNICATION IV	17:00
			18:00
			19:00

SCIENTIFIC PROGRAM AT A GLANCE

SATURDAY, APRIL 5TH, 2025

	Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
07:00			
08:00			
09:00	Break		
	KEYNOTE LECTURE KEY05 Neoadjuvant therapy: a new standard of care for melanoma?		
10:00	SYMPOSIUM SY45 Primary prevention of skin cancer	SYMPOSIUM SY46 Is there a future for sentinel node biopsy?	DERMOSCOPY CONTEST I
	Break		
11:00	KEYNOTE LECTURE KEY06 Improving outcomes in melanoma beyond the standard use of immune checkpoint blockers		
	KEYNOTE LECTURE KEY07 The future of non-melanoma skin cancer treatment		
12:00	SYMPOSIUM SY49 New devices for ...	SYMPOSIUM SY50 Management of adverse events in immuno-oncology	DERMOSCOPY CONTEST II
	POSTER AWARDS		
13:00	Break		

Skalkotas Hall 380 seats/Level -1			M3 180 seats/Level -1	M2 150 seats/Level -1	07:00
SOCRATES' DIALOGUES IV: AN INTERACTIVE MORNING SESSION Prognostic and predictive biomarkers for melanoma			SOCRATES' DIALOGUES V: AN INTERACTIVE MORNING SESSION Challenges in neoadjuvant therapy	SOCRATES' DIALOGUES VI: AN INTERACTIVE MORNING SESSION How to build up a career in dermato-oncology?	08:00
SYMPOSIUM SY47 Patient Advocacy Groups			SYMPOSIUM SY48 Interdisciplinary tumor board: challenging skin cancer cases II		09:00
					10:00
					11:00
SYMPOSIUM SY51 Promising agents for PD1-refractory patients			SYMPOSIUM SY52 Melanoma pathology – genomics and morphology	FREE COMMUNICATION V	12:00
					13:00

SATURDAY, APRIL 5TH, 2025

	Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
13:00	Break		
	SYMPOSIUM SY53 Treatment at the end of the life	SYMPOSIUM SY54 Management of adverse events in targeted therapies	SYMPOSIUM SY55 Management of lentigo maligna and acral lentiginous melanomas
14:00			
	SYMPOSIUM SY59 Dermoscopy 2: Dermoscopy in melanoma management	SYMPOSIUM SY60 Actinic keratosis: current treatment and future perspectives	SATELLITE SYMPOSIUM SAT14 Further Sponsor
15:00			
	SYMPOSIUM SY63 Dermoscopy 3: Difficult clinical scenarios	SYMPOSIUM SY64 Surgery of stage IV melanoma: still needed?	SATELLITE SYMPOSIUM SAT15 Further Sponsor
16:00			
	Farewell & Closing Remarks		
17:00			
18:00			
19:00			

Skalkotas Hall 380 seats/Level -1	M3 180 seats/Level -1	M2 150 seats/Level -1	
			13:00
SYMPOSIUM SY56 Immune checkpoint inhibition in immunocompromised patients	SYMPOSIUM SY57 Melanocytic lesions of unknown potential: biology, prognosis, treatment and follow-up	SYMPOSIUM SY58 Cutaneous melanoma risk and progression in Mediterranean populations and beyond (MelaNostrum)	
			14:00
SYMPOSIUM SY61 Diagnosis and management of cutaneous T-and B-cell lymphomas	SYMPOSIUM SY62 Interdisciplinary tumor board: challenging skin cancer cases III		
			15:00
SYMPOSIUM SY65 Current primary staging and follow-up recommendations for melanoma patients	SYMPOSIUM SY66 Genetic susceptibility of melanoma and cancer syndromes		
			16:00
			17:00
			18:00
			19:00

SCIENTIFIC PROGRAM

THURSDAY, APRIL 3RD, 2025

08:00–08:15	Trianti Hall	OPENING CEREMONY Alexander Stratigos, Athens, Greece
08:15–09:15	Trianti Hall	SYMPOSIUM SY01 Controversies – Skin cancer screening should be abandoned! CHAIRS: Claus Garbe, Tuebingen, Germany Alexander Stratigos, Athens, Greece Yes: Susana Puig, Barcelona, Spain No: Peter Mohr, Buxtehude, Germany
08:15–09:15	Banqueting Hall	SYMPOSIUM SY02 Dermoscopy 1: Total body photography, digital dermoscopy and scanners: indications and procedures CHAIRS: Harald Kittler, Vienna, Austria Josep Malvehy, Barcelona, Spain 08:15–08:30 Innovative advances in total body photography Josep Malvehy, Barcelona, Spain 08:35–08:50 Artificial intelligence-assisted sequential imaging for high-risk patients Harald Kittler, Vienna, Austria 08:55–09:10 Population screening using total body imaging Katrien Vossaert, Gent, Belgium
08:15–09:15	Mitropoulos Hall	SYMPOSIUM SY03 Prognostic and predictive biomarkers in melanoma CHAIRS: Christian Blank, Amsterdam, The Netherlands Bastian Schilling, Frankfurt, Germany 08:15–08:30 What are biomarkers worth in a changing early stage disease treatment landscape? Christian Blank, Amsterdam, The Netherlands 08:35–08:50 Biomarkers and extra-cutaneous melanoma Bastian Schilling, Frankfurt, Germany 08:55–09:10 Biomarkers of toxicity from targeted and immunotherapy Vincent Sibaud, Toulouse, France

08:15–09:15	Skalkotas Hall	SYMPOSIUM SY04 Squamous cell carcinoma (SCC): epidemiology and management CHAIRS: Chrysalyne Schmults, Boston, USA Ralf Gutzmer, Minden, Germany 08:15–08:27 Diagnosis and risk stratification in cutaneous SCC Chrysalyne Schmults, Boston, USA 08:30–08:42 Epidemiology of cutaneous SCC Ulrike Leiter-Stöppke, Tuebingen, Germany 08:45–08:57 Adjuvant/neoadjuvant treatment of cutaneous SCC Vishal Patel, Washington, USA 09:00–09:12 Treatment of cutaneous SCC in the inoperable situation Ralf Gutzmer, Minden, Germany
08:15–09:15	M3	SYMPOSIUM SY05 Merkel cell carcinoma: epidemiology, surgery and radiology CHAIRS: Jürgen Becker, Essen, Germany Shailender Bhatia, Seattle, USA 08:15–08:27 Epidemiology Georg Lodde, Essen, Germany 08:30–08:42 Surgery Alexander van Akkooi, Sydney, Australia 08:45–08:57 Prognostication Jürgen Becker, Essen, Germany 09:00–09:12 Radiotherapy Shailender Bhatia, Seattle, USA
09:15–10:15	Trianti Hall	SYMPOSIUM SY06 Controversies – Does melanoma follow-up contribute to overall survival improvement? CHAIRS: Alexander Eggermont, Utrecht, The Netherlands Ralf Gutzmer, Minden, Germany Yes: Ulrike Leiter-Stöppke, Tuebingen, Germany No: Alexander van Akkooi, Sydney, Australia
09:15–10:15	Banqueting Hall	SATELLITE SYMPOSIUM SAT01 Gold Sponsor Detailed Information Page 68–74

09:15–10:15	Mitropoulos Hall	SYMPOSIUM SY07 Melanoma guidelines around the world CHAIRS: Claus Garbe, Tuebingen, Germany Paolo Ascierto, Naples, Italy Omid Hamid, Los Angeles, USA 09:15–09:30 EADO (European Association of Dermato-Oncology) Claus Garbe, Tuebingen, Germany 09:30–09:45 ESMO (European Society for Medical Oncology) Paolo Ascierto, Naples, Italy 09:45–10:00 NCCN (European Society for Medical Oncology) Omid Hamid, Los Angeles, USA 10:00–10:15 JDA (Japanese Dermatological Association) and (JSCS) Japanese Skin Cancer Society Satoshi Fukushima, Kumamoto, Japan
09:15–10:15	Skalkotas Hall	SYMPOSIUM SY08 Intralesional therapies of skin cancer CHAIRS: Christoph Höller, Vienna, Austria Mario Mandala, Perugia, Italy 09:15–09:27 State of the art Michael Migden, Houston, USA 09:30–09:42 New targets and systemic immunological activity Adil Daud, San Francisco, USA 09:45–09:57 Combining systemic and intralesional therapy: challenges and opportunities Reinhard Dummer, Zurich, Switzerland 10:00–10:12 Intralesional neoadjuvant approaches: ready for prime time? Christoph Höller, Vienna, Austria
09:15–10:15	M3	SYMPOSIUM SY09 Liquid biopsy as a decision maker in melanoma? CHAIRS: Christoffer Gebhardt, Hamburg, Germany Evi Lianidou, Athens, Greece Paul Lorigan, Manchester, United Kingdom 09:15–09:30 The potential of liquid biopsy for the management of cancer patients Evi Lianidou, Athens, Greece 09:35–09:50 Ultra-sensitive tumor-informed ctDNA measurement in melanoma patients receiving checkpoint-inhibition Christoffer Gebhardt, Hamburg, Germany 09:55–10:10 Ongoing and potential trials of ctDNA based strategies in melanoma Paul Lorigan, Manchester, United Kingdom

10:15–10:45		Break
10:45–11:15	Trianti Hall	KEYNOTE LECTURE KEY01 CHAIR: Alexander Stratigos, Athens, Greece Skin cancer epidemic: is there light at the end of the tunnel? David Whiteman, Brisbane, Australia
11:15–11:45	Trianti Hall	KEYNOTE LECTURE KEY02 CHAIR: Alexander Stratigos, Athens, Greece The journey from melanocytes to melanoma Alan Hunter Shain, San Francisco, USA
11:45–12:45	Trianti Hall	SATELLITE SYMPOSIUM SAT02 Platinum Sponsor Detailed Information Page 68–74
12:45–13:45		Break
13:45–14:45	Trianti Hall	SYMPOSIUM SY10 Melanoma classifications: past, present and future CHAIRS: Jeffrey Gershenwald, Houston, USA Richard Scolyer, Sydney, Australia 13:45–14:00 What is a melanocytoma and how should they be classified and managed? Richard Scolyer, Sydney, Australia 14:05–14:20 Beyond the 8th edition American Joint Committee on Cancer (AJCC) melanoma staging system Jeffrey Gershenwald, Houston, USA 14:25–14:40 Should we change the term melanoma in situ? David Elder, Pennsylvania, USA
13:45–14:45	Banqueting Hall	SATELLITE SYMPOSIUM SAT03 Gold Sponsor Detailed Information Page 68–74

13:45–14:45	Mitropoulos Hall	SYMPOSIUM SY11 Treatment of cutaneous lymphomas: what's coming from the pipeline? CHAIRS: Emmanuella Guenova, Linz, Austria Pietro Quaglino, Turin, Italy 13:45–14:00 Recently approved treatment approaches Chalid Assaf, Krefeld, Germany 14:05–14:20 Products under current clinical developments Pietro Qualigno, Turin, Italy 14:25–14:55 Translational evidence: from bench to bedside Emmanuella Guenova, Linz, Austria
13:45–14:45	Skalkotas Hall	SYMPOSIUM SY12 Adoptive T-Cell transfer (tumor-infiltrating lymphocytes, TIL) for advanced melanomas CHAIRS: Inge Marie Svane, Copenhagen, Denmark Gal Markel, Tel Aviv, Israel 13:45–14:00 The art of selecting the right patients for TIL therapy Inge Marie Svane, Copenhagen, Denmark 14:05–14:20 The treatment journey and destination of a TIL patient Troels Holz Borch, Copenhagen, Denmark 14:25–14:40 What is the next step for TIL therapies? Gal Markel, Tel Aviv, Israel
13:45–14:45	M3	SYMPOSIUM SY13 Interdisciplinary tumor board: challenging skin cancer cases I CHAIRS: Selma Ugurel, Essen, Germany Zeljko Mijuskovic, Belgrade, Serbia Rodrigo Munhoz, Sao Paolo, Brazil 13:45–13:57 Case 1 Zeljko Mijuskovic, Belgrad, Serbia 14:00–14:12 Case 2 Selma Ugurel, Essen, Germany 14:15–14:27 Case 3 Andrea Forschner, Tuebingen, Germany 14:30–14:42 Case 4 Rodrigo Munhoz, Sao Paolo, Brazil

13:45–14:45	M2	SYMPOSIUM SY14 Overdiagnosis of melanoma: a real problem? CHAIR: Hensin Tsao, Boston, USA Axel Hauschild, Kiel, Germany 13:45–14:00 ...in Europe Josep Malvehy, Barcelona, Spain 14:05–14:20 ...in Australia David Whiteman, Brisbane, Australia 14:25–14:40 ...in the USA Hensin Tsao, Boston, USA
14:45–15:45	Triantl Hall	SYMPOSIUM SY15 Neoadjuvant treatment of melanoma CHAIRS: Christian Blank, Amsterdam, The Netherlands Georgina Long, Sydney, Australia 14:45–14:57 Clinical development of neoadjuvant immunotherapy in melanoma Georgina Long, Sydney, Australia 15:00–15:12 Next steps towards full personalization of neoadjuvant melanoma therapy Christian Blank, Amsterdam, The Netherlands 15:15–15:27 What can we learn from other cancers? Alexander Eggermont, Utrecht, The Netherlands 15:30–15:42 Making the pathological response criteria more efficient and pan-cancer Julie Stein Deutsch, Baltimore, USA
14:45–15:45	Banqueting Hall	SYMPOSIUM SY16 Basal cell carcinoma (BCC): epidemiology and management CHAIRS: Ricardo Vieira, Coimbra, Portugal Clio Dessinioti, Athens, Greece 14:45–14:57 Epidemiology of BCC Clio Dessinioti, Athens, Greece 15:00–15:12 Topical and interventional management for BCC: recommendations and patient selection Klara Mosterd, Maastricht, The Netherlands 15:15–15:27 Surgical management of BCC: case scenarios Ricardo Vieira, Coimbra, Portugal 15:30–15:42 The evolution of systemic therapy for advanced BCC Alexander Stratigos, Athens, Greece

14:45–15:15	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT04 Silver Sponsor Detailed Information Page 68–74
15:15–15:45	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT05 Silver Sponsor Detailed Information Page 68–74
14:45–15:45	Skalkotas Hall	SYMPOSIUM SY17 Immunotherapy of Merkel cell carcinoma (MCC) CHAIRS: Céleste Lebbé, Paris, France Iwona Lugowska, Warsaw, Poland 14:45–15:00 The benefits of immunotherapy in non-immunocompromised MCC patients Iwona Lugowska, Warsaw, Poland 15:05–15:20 What is the benefit/risk of immunotherapy in immunosuppressed individuals? Céleste Lebbé, Paris, France 15:25–15:40 Immunotherapy for MCC: do we have prognostic and/or predictive biomarkers? Jürgen Becker, Essen, Germany
14:45–15:45	M3	SYMPOSIUM SY18 Primary ocular melanoma: genetics, clinical appearance and treatment CHAIRS: Nikolaos Bechrakis, Essen, Germany Helen Kalirai, Liverpool, United Kingdom 14:45–15:00 Biology, genetics and pathology of conjunctival and uveal melanomas Helen Kalirai, Liverpool, United Kingdom 15:05–15:20 Diagnosis of conjunctival and uveal melanomas Heinrich Heimann, Liverpool, United Kingdom 15:25–15:40 Treatment of conjunctival and uveal melanomas Nikolaos Bechrakis, Essen, Germany
14:45–15:45	M2	FREE COMMUNICATION I CHAIRS: Teresa Amaral, Tuebingen, Germany Konstantinos Liopyris, Athens, Greece
15:45–16:15		Break

16:15–17:45	Trianti Hall	SYMPOSIUM SY19 Artificial Intelligence (AI) in dermatology-oncology CHAIRS: Julia Winkler, Heidelberg, Germany Allan C. Halpern, New York, USA Konstantinos Liopyris, Athens, Greece 16:15–16:27 Introduction to the current and evolving trends on AI Harald Kittler, Vienna, Austria 16:30–16:42 Current state of imaging in dermatology-oncology Allan C. Halpern, New York, USA 16:45–16:57 Current state of commercialization and implementation of AI in dermatology-oncology Josep Malvehy, Barcelona, Spain 17:00–17:12 Medicolegal and privacy issues on the use of AI Peter Soyer, Brisbane, Australia 17:15–17:27 Limitations on the use of AI in dermatology-oncology Konstantinos Liopyris, Athens, Greece 17:30–17:42 Opportunities and challenges of AI in dermatology-oncology Julia Winkler, Heidelberg, Germany
16:15–17:45	Banqueting Hall	SYMPOSIUM SY20 Registries for real world treatment data and outcome research CHAIRS: Michael Weichenthal, Kiel, Germany Ana-Maria Forsea, Bucharest, Romania Peter Mohr, Buxtehude, Germany 16:15–16:27 Cancer registries – why are they important for skin cancer control Ana-Maria Forsea, Bucharest, Romania 16:30–16:42 Where big data fails – a critical view on real-world outcome research Michael Weichenthal, Kiel, Germany 16:45–16:57 Systemic therapy in locally advanced basal cell carcinoma and impact of the EADO classification Eve Maubec, Bobigny, France 17:00–17:12 Adjuvant therapy in melanoma: new insights from real life data Peter Mohr, Buxtehude, Germany 17:15–17:27 Immune related side effects beyond clinical trials using registry data Karijn Suijkerbuijk, Utrecht, The Netherlands 17:30–17:42 The role of BRAF + MEK-inhibitors in clinical practice 2025 Inge Marie Svane, Copenhagen, Denmark

16:15–16:45	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT06 Further Sponsor Detailed Information Page 68–74
16:45–17:45	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT07 Further Sponsor Detailed Information Page 68–74
16:15–17:45	Skalkotas Hall	SYMPOSIUM SY21 Memorial Symposium for Jeff Weber Drug resistance to immune checkpoint inhibition CHAIRS: Thomas Gajewski, Chicago, USA Grant McArthur, Melbourne, Australia Olivier Michielin, Geneva, Switzerland 16:15–16:30 Jeff Weber – A life dedicated to melanoma research Thomas Gajewski, Chicago, USA 16:30–16:50 Cross resistance between targeted therapies and immune checkpoint inhibition Grant McArthur, Melbourne, Australia 16:55–17:15 Systemic therapies to treat PD-1 resistance Olivier Michielin, Geneva, Switzerland 17:20–17:40 Understanding mechanisms of immunotherapy response versus resistance through the tumor microenvironment Thomas Gajewski, Chicago, USA

16:15–17:45	M3	SYMPOSIUM SY22 Skin Care in Organ Transplant Patients Europe (SCOPE) CHAIRS: Catherine Harwood, London, United Kingdom Ulrike Leiter-Stöppke, Tuebingen, Germany Alexandra Geusau, Vienna, Austria 16:15–16:20 Welcome and introduction Alexandra Geusau, Vienna, Austria 16:20–16:32 How to set up a specialty clinic for the dermatologic care of solid-organ transplant recipients – the British Experience Charlotte Proby, Dundee, United Kingdom 16:35–16:47 Prevention of NMSC in organ transplant recipients Alexandra Geusau, Vienna, Austria 16:50–17:05 The ‘SCOPE-ITSCC metastases study’: Transcriptome-based tumor stratification to better identify cutaneous squamous cell carcinomas at risk for metastases in organ transplant recipients Chrysalyne Schmults, Boston, USA 17:10–17:20 Frequently asked, difficult to answer – How to proceed with transplantation post melanoma? Carla Ferrandiz-Pulido, Barcelona, Spain 17:20–17:30 Frequently asked, difficult to answer – How to proceed with transplantation post SCC? Ulrike Leiter-Stöppke, Tuebingen, Germany 17:30–17:40 Frequently asked, difficult to answer – How to proceed with transplantation post rare skin cancer? Catherine Harwood, London, United Kingdom 17:40–17:45 Closing remarks Alexandra Geusau, Vienna, Austria Ulrike Leiter-Stöppke, Tuebingen, Germany Catherine Harwood, London, United Kingdom
16:15–17:45	M2	FREE COMMUNICATION II CHAIRS: Dimitris Bafaloukos, Athens, Greece Jürgen Becker, Essen, Germany
18:00–20:00		Welcome Reception

SCIENTIFIC PROGRAM

FRIDAY, APRIL 4TH, 2025

07:30–08:15	M2	SOCRATES' DIALOGUES III: AN INTERACTIVE MORNING SESSION The role of microbiome for immunotherapies MODERATOR: Thomas Gajewski, Chicago, USA
07:30–08:15	Skalkotas Hall	SOCRATES' DIALOGUES I: AN INTERACTIVE MORNING SESSION Treatment refractory stage IV melanomas: what do I do? MODERATOR: Teresa Petrella, Toronto, Canada
07:30–08:15	M3	SOCRATES' DIALOGUES II: AN INTERACTIVE MORNING SESSION Women in dermato-oncology MODERATOR: Carola Berking, Erlangen, Germany
08:15–08:30	Break	
08:30–09:30	Trianti Hall	SYMPOSIUM SY23 Melanoma research CHAIRS: Liz Patton, Edinburgh, United Kingdom Dirk Schadendorf, Essen, Germany 08:30–08:42 Novel insights from disease models in melanoma Liz Patton, Edinburgh, United Kingdom 08:45–08:57 Metabolic vulnerabilities in melanoma Alpaslan Tasdogan, Essen, Germany 09:00–09:12 Tertiary lymphoid structures in melanoma Göran Jönsson, Lund, Sweden 09:15–09:27 Mitochondria oncogenetics in melanoma Payam Gammage, Glasgow, Scotland

08:30–09:30	Banqueting Hall	SYMPOSIUM SY24 Congenital nevi: risk and management CHAIRS: Veronica Kinsler, London, United Kingdom Luc Thomas, Lyon, France 08:30–08:50 A mouse model of NRAS-driven congenital melanocytic nevus. David Fisher, Cambridge, USA 08:50–09:10 Congenital-type nevus of the nail unit, clinical presentation, prognosis and management Luc Thomas, Lyon, France 09:10–09:30 RNA therapy for congenital melanocytic naevi Veronica Kinsler, London, United Kingdom
08:30–09:30	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT08 Silver Sponsor Detailed Information Page 68–74
08:30–09:30	Skalkotas Hall	SYMPOSIUM SY25 Management of mucosal melanoma CHAIRS: Paul Lorigan, Manchester, United Kingdom Jun Guo, Beijing, China 08:30–08:42 Neoadjuvant and adjuvant therapies for mucosal melanoma Bin Lian, Beijing, China 08:45–08:57 Clinical guidelines for the management of mucosal melanoma Paul Lorigan, Manchester, United Kingdom 09:00–09:12 Treatment options and challenges in advanced mucosal melanoma Jun Guo, Beijing, China 09:15–09:27 Case discussion – Case discussions on the management of anorectal and sinunasal melanomas Paul Nathan, London, United Kingdom

08:30–09:30	M3	SYMPOSIUM SY26 Microbiome in cancer: more than gut feelings? CHAIRS: Jennifer Wargo, Houston, USA Laurence Zitvogel, Paris, France Thomas Gajewski, Chicago, USA 08:30–08:45 Targeting the microbiome to promote health and end cancer Jennifer Wargo, Houston, USA 08:50–09:05 Intestinal biomarkers in cancer immunosurveillance Laurence Zitvogel, Paris, France 09:10–09:25 Mechanisms of regulation of anti-tumor immunity via the commensal microbiota Thomas Gajewski, Chicago, USA
08:30–10:30	M2	FREE COMMUNICATION III CHAIRS: Thomas Dirschka, Wuppertal, Germany Helen Gogas, Athens, Greece
09:30–10:30	Trianti Hall	SYMPOSIUM SY27 Controversies – Is there a future for sentinel node biopsy? CHAIRS: Alberto Wainstein, Belo Horizonte, Brazil Piotr Rutkowski, Warsaw, Poland Yes: Vernon Sondak, Tampa, USA No: Alexander van Akkooi, Sydney, Australia
09:30–10:30	Banqueting Hall	SATELLITE SYMPOSIUM SAT09 Gold Sponsor Detailed Information Page 68–74
09:30–10:30	Mitropoulos Hall	SYMPOSIUM SY28 Drug resistance to targeted therapies CHAIRS: Bart Neyns, Brussels, Belgium Olivier Michielin, Geneva, Switzerland 09:30–09:42 Introduction to resistance mechanisms Olivier Michilien, Geneva, Switzerland 09:45–09:57 Preclinical insight in the molecular basis of response and resistance to targeted therapy in melanoma Poulikos Poulidakos, New York, USA 10:00–10:12 Mechanisms of acquired resistance to targeted therapy in melanoma Roger Lo, Los Angeles, USA 10:15–10:30 Clinical avenues to overcome resistance to targeted therapy in melanoma Bart Neyns, Brussels, Belgium

09:30–10:30	Skalkotas Hall	SYMPOSIUM SY29 Molecular tumor board for skin cancers CHAIRS: Teresa Amaral, Tuebingen, Germany Ryan Sullivan, Boston, USA Richard Scolyer, Sydney, Australia 09:30–09:45 Case 1: Novel therapies for BRAF and neuroblastoma RAS viral oncogene homolog mutant melanoma Teresa Amaral, Tuebingen, Germany 09:50–10:05 Case 2: Molecular targeting of other genetic alterations – including epidermal growth factor receptor (EGFR), neurotrophic tyrosine receptor kinase (NTRK), KIT, and tumor mutational burden (TMB) Ryan Sullivan, Boston, USA 10:10–10:25 Case 3: Personalised immunotherapy platform for advanced stage melanoma patients Richard Scolyer, Sydney, Australia
09:30–10:30	M3	SYMPOSIUM SY30 Treatment of field cancerization including actinic cheilitis CHAIRS: Nicole Kelleners-Smeets, Maastricht, The Netherlands Maria Concetta Fargnoli, Rome, Italy Markus Heppt, Erlangen, Germany 09:30–09:45 Hot of the press – what's new in the treatment of actinic keratosis and field cancerization? Markus Heppt, Erlangen, Germany 09:50–10:05 Therapeutic options for actinic cheilitis Maria Concetta Fargnoli, Rome, Italy 10:10–10:25 Treatment of actinic keratosis from patients' perspective Nicole Kelleners-Smeets, Maastricht, The Netherlands
10:30–11:00		Break
11:00–12:00	Trianti Hall	SYMPOSIUM SY31 Adjuvant treatment of melanoma CHAIRS: Sanjiv Agarwala, Philadelphia, USA Hussein Tawbi, Houston, USA Axel Hauschild, Kiel, Germany 11:00–11:12 Setting the stage: current adjuvant treatment modalities Sanjiv Agarwala, Philadelphia, USA 11:15–11:27 Adjuvant and which strategy (IO vs targeted) in the light of neoadjuvant breakthroughs Mario Mandala, Perugia, Italy 11:30–11:42 Should we treat lower risk patients (stage IB/IIA/IIB) Axel Hauschild, Kiel, Germany 11:45–11:57 Innovative treatment strategies: What comes next? Hussein Tawbi, Houston, USA

11:00–12:00	Banqueting Hall	SYMPOSIUM SY32 Management of brain metastases CHAIRS: Michael Davies, Houston, USA Helen Gogas, Athens, Greece Omid Hamid, Los Angeles, USA 11:00–11:12 Update on immune checkpoint inhibitors for melanoma brain metastases Helen Gogas, Athens, Greece 11:15–11:27 Targeted therapy for and molecular biology of melanoma brain metastases Michael Davies, Houston, USA 11:30–11:42 New approaches from LMD and brain metastases from melanoma Omid Hamid, Los Angeles, USA 11:45–11:57 Brain metastases – The value of interdisciplinary management Friedegund Meier, Dresden, Germany
11:00–12:00	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT10 Further Sponsor Detailed Information Page 68–74
11:00–12:00	Skalkotas Hall	SYMPOSIUM SY33 Radiotherapy for melanoma and other skin cancers: where are we now? (ESTRO) CHAIRS: Luca Tagliaferri, Rome, Italy Reinhard Dummer, Zurich, Switzerland 11:00–11:12 Grenz Ray and soft-XRay therapy from a dermatological perspective Reinhard Dummer, Zurich, Switzerland 11:15–11:27 Value-based medicine: “personalized patient centric approach” and integrated therapies in non-melanoma skin cancer Luca Tagliaferri, Rome, Italy 11:30–11:42 Advances in External Beam Radiotherapy (EBRT) for the management of NMSC and melanoma: what we need to know Agata Rembielak, Manchester, United Kingdom 11:45–11:57 Advances in Interventional Radiotherapy (brachytherapy) for the management of NMSC and melanoma: what we need to know Piotr Wojcieszek, Gliwice, Poland

11:00–12:00	M3	SYMPOSIUM SY34 Surgical pearls in the treatment of skin cancer CHAIRS: Ricardo Vieira, Coimbra, Portugal Roland Kaufmann, Frankfurt, Germany 11:00–11:09 All-time tips and tricks Roland Kaufmann, Frankfurt, Germany 11:12–11:21 My pearls around the mouth Elena Rossi, Modena, Italy 11:24–11:33 Surgical pearls in periocular cancer excisions Ricardo Vieira, Coimbra, Portugal 11:36–11:45 My pearls around the cheek and temple Myrto Trakatelli, Thessaloniki, Greece 11:48–11:57 My pearls in repairs of the nose David Moreno, Seville, Spain
11:00–12:00	M2	SYMPOSIUM SY35 Rare Tumors (adnexal, sebaceous, dermatofibrosarcoma protuberans) CHAIR: Philippe Saiag, Paris, France David Adams, Cambridge, United Kingdom 11:00–11:15 The genomic landscape of rare adnexal tumours: The Dermatlas Project David Adams, Cambridge, United Kingdom 11:20–11:35 Recent clinical advances in adnexal tumors Thomas Jouary, Bordeaux, France 11:40–11:55 Dermatofibrosarcoma protuberans: update of the EADO-EORTC guideline Philippe Saiag, Paris, France
12:00–13:00	Trianti Hall	SATELLITE SYMPOSIUM SAT11 Platinum Sponsor Detailed Information Page 68–74
13:00–14:00		Break
14:00–14:30	Trianti Hall	KEYNOTE LECTURE KEY03 CHAIR: Christopher Höller, Vienna, Austria Diagnostic tools for skin cancer detection beyond dermoscopy Josep Malvehy, Barcelona, Spain
14:30–15:00	Trianti Hall	KEYNOTE LECTURE KEY04 CHAIR: Jeffrey Gershenwald, Houston, USA New diagnostics, prognostic biomarkers and systemic therapy strategies sharply reduce the need for surgery in melanoma Alexander Eggermont, Utrecht, The Netherlands

15:00–16:00	Trianti Hall	SATELLITE SYMPOSIUM SAT12 Platinum Sponsor Detailed Information Page 68–74
15:00–16:00	Trianti Hall	SYMPOSIUM SY36 Immune checkpoint inhibition for non-melanoma skin cancer CHAIRS: Paolo Ascierto, Naples, Italy Dirk Schadendorf, Essen, Germany 15:00–15:15 Basal cell carcinoma: strategies to treat in 2025 Dirk Schadendorf, Essen, Germany 15:20–15:35 Cutaneous squamous cell carcinoma – Treatment options in adjuvant, neoadjuvant and palliative setting Paolo Ascierto, Naples, Italy 15:40–15:55 Merkel cell carcinoma – guideline update and more Iwona Lugowska, Warsaw, Poland
15:00–16:00	Banqueting Hall	SYMPOSIUM SY37 High-risk melanocytic nevi: are they existing, and how to define what to do? CHAIRS: Veronique Bataille, London, United Kingdom Giuseppe Argenziano, Naples, Italy 15:00–15:15 Melanocytic naevi from a biological and evolutionary perspective Veronique Bataille, London, United Kingdom 15:20–15:35 High-risk melanocytic nevi: definition from a clinical perspective Giuseppe Argenziano, Naples, Italy 15:40–15:55 High-risk melanocytic nevi: definition from a histopathologic perspective Harald Kittler, Vienna, Austria
15:00–16:00	Skalkotas Hall	SYMPOSIUM SY38 Drug access across the world: approval is not reimbursement! CHAIRS: Lidija Kandolf, Belgrade, Serbia Paul Lorigan, Manchester, United Kingdom 15:00–15:15 Access to skin cancer medications in Europe Lidija Kandolf, Belgrade, Serbia 15:20–15:35 Access to skin cancer medications in Latin America Rodrigo Munhoz, Sao Paulo, Brazil 15:40–15:55 The role of academia, industry and regulatory agencies in developing practice-defining trials Paul Lorigan, Manchester, United Kingdom

15:00–16:00	M3	SYMPOSIUM SY39 Cutaneous sarcomas: diagnosis and treatment CHAIRS: Stephan Grabbe, Mainz, Germany Rodrigo Munhoz, Sao Paulo, Brazil 15:00–15:12 Key questions about cutaneous sarcomas Stephan Grabbe, Mainz, Germany 15:15–15:27 Dermatofibrosarcoma protuberans Philippe Saiag, Paris, France 15:30–15:42 Pleomorphic Dermal Sarcoma & Atypical Fibroxanthoma Rodrigo Munhoz, Sao Paulo, Brazil 15:45–15:57 Angiosarcoma/Kaposi's sarcoma Céléste Lebbé, Paris, France
15:00–16:00	M2	SYMPOSIUM SY40 Mohs micrographic surgery and skin cancer management CHAIRS: Joseph Alcalay, Tel-Aviv, Israel Sotirios Theocharis, Athens, Greece 15:00–15:15 Mohs vs Slow Mohs: Pros and cons Roland Kaufmann, Frankfurt, Germany 15:20–15:35 Pitfalls in Mohs surgery Ricardo Vieira, Coimbra, Portugal 15:40–15:55 Beyond the scalpel – when Mohs surgery is not enough Joseph Alcalay, Tel-Aviv, Israel
16:00–16:15		Break
16:15–17:15	Triant Hall	SYMPOSIUM SY41 Global epidemiologic trends and survival in skin cancer CHAIRS: Zoe Venables, Norwich, United Kingdom David Whiteman, Brisbane, Australia 16:15–16:27 Global Melanoma Trends: Insights from Swedish Data and Projections for the Future Hildur Helgadóttir, Stockholm, Sweden 16:30–16:42 Trends in melanoma incidence in Australia by age and ancestry: public health impact or population admixture? David Whiteman, Brisbane, Australia 16:45–16:57 Long-term survival and causes of death across Breslow thickness categories Anne Cust, Sydney, Australia 17:00–17:12 Shifting skin cancer patterns in England: incidence and mortality trends over the past 20 years Zoe Venables, Norwich, United Kingdom

16:15–17:15	Banqueting Hall	SYMPOSIUM SY42 Metastatic uveal melanoma – current and emerging treatment options CHAIRS: Paul Nathan, London, United Kingdom Jessica Hassel, Heidelberg, Germany Heather Shaw, London, United Kingdom 16:15–16:30 First-line immunotherapy of metastatic uveal melanoma Jessica Hassel, Heidelberg, Germany 16:35–16:50 Adjuvant treatment of high risk uveal melanoma Paul Nathan, London, United Kingdom 16:55–17:10 New targets and approaches in development Heather Shaw, London, United Kingdom
16:15–17:15	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT13 Further Sponsor Detailed Information Page 68–74
16:15–17:45	Skalkotas Hall	SYMPOSIUM SY43 Occupational skin cancer: The sleeping giant (4th Multi-stakeholder summit) MODERATORS: Swen-Malte John, Osnabrueck, Germany Myrto Trakatelli, Thessaloniki, Greece 16:15–16:30 Welcoming remarks and Introduction to Summit 16:15–16:19 The Stakeholder Summit Journey Swen Malte John, Osnabrueck, Germany 16:19–16:24 EADO Josep Malvehy, Barcelona, Spain 16:24–16:27 GlobalSkin Jennifer Austin, Ottawa, Canada 16:27–16:30 EADV TBA 16:30–17:10 Prevention and acknowledgement of occupational skin cancer (Short intros) 16:30–16:36 World Health Organisations (WHO) perspectives Emilie van Deventer 16:36–16:42 Skin cancer as an occupational disease – the ILO perspective Shengli Niu 16:42–16:48 Economic perspective of skin cancer prevention and registries Matthias Augustin, Hamburg, Germany 16:48–16:54 The Australian experience with skin cancer prevention David Whiteman, Brisbane, Australia 16:54–16:58 Representative Greek ministry of Health 16:58–17:02 Representative Greek ministry of Labour 17:02–17:06 EU-representative DG Sante 17:06–17:10 EU-representative DG Employment 17:10–17:40 Panel Discussion all speakers 17:40–17:45 Wrap up and Global Call to Action Myrto Trakatelli, Thessaloniki, Greece

16:15–17:15	M3	SYMPOSIUM SY44 Skin cancer on colored skin: clinical appearance and treatment CHAIRS: Dagmar Whitaker, Cape Town, South Africa Aleksandar Sekulic, Phoenix, USA 16:15–16:27 Skin cancer in dark skin – a bigger problem than we think? Dagmar Whitaker, Cape Town South Africa 16:30–16:42 Challenges of skin cancer in the Asian population Hisashi Uhara, Sapporo, Japan 16:45–16:57 Melanoma in dark skin – how can we increase awareness and achieve better disease outcomes? Willie Visser, Stellenbosch, South Africa 17:00–17:12 Treatment innovations and pipeline products for AK Aleksandar Sekulic, Phoenix, USA
16:15–17:45	M2	FREE COMMUNICATION IV

SCIENTIFIC PROGRAM

SATURDAY, APRIL 5TH, 2025

07:30–08:15	M2	SOCRATES' DIALOGUES VI: AN INTERACTIVE MORNING SESSION How to build up a career in dermato-oncology? MODERATOR: Alexander Stratigos, Athens, Greece
07:30–08:15	Skalkotas Hall	SOCRATES' DIALOGUES IV: AN INTERACTIVE MORNING SESSION Prognostic and predictive biomarkers for melanoma MODERATOR: Reinhard Dummer, Zurich, Switzerland
07:30–08:15	M3	SOCRATES' DIALOGUES V: AN INTERACTIVE MORNING SESSION Challenges in neoadjuvant therapy MODERATOR: Sapna Patel, Denver, USA
08:15–08:30		Break
08:30–09:00	Trianti Hall	KEYNOTE LECTURE KEY05 CHAIR: Helen Gogas, Athens, Greece Neoadjuvant therapy: a new standard of care for melanomas? Georgina Long, Sydney, Australia
09:00–10:00	Trianti Hall	SYMPOSIUM SY45 Primary prevention of skin cancer CHAIRS: Veronique del Marmol, Brussels, Belgium Mirna Situm, Zagreb, Croatia 09:00–09:12 Is primary prevention effective at all? David Whiteman, Brisbane, Australia 09:15–09:27 Systemic chemoprevention: a holy grail? Peter Soyer, Brisbane, Australia 09:30–09:42 Sunscreen: friend or foe? Veronique del Marmol, Brussels, Belgium 09:45–09:57 23 years of skin cancer prevention campaigns in Croatia Mirna Situm, Zagreb, Croatia

09:00–10:00	Banqueting Hall	SYMPOSIUM SY46 Is there a future for sentinel node biopsy? CHAIRS: Alexander van Akkooi, Sydney, Australia Merrick I. Ross, Houston, USA 09:00–09:15 Sentinel lymph node dissection (SLND) in cutaneous squamous cell carcinoma Merrick I. Ross, Houston, Texas 09:20–09:35 SLND in Merkel cell carcinoma Alexander van Akkooi, Sydney, Australia 09:40–09:55 SLND in melanoma Piotr Rutkowski, Warsaw, Poland
09:00–10:00	Mitropoulos Hall	DERMOSCOPY CONTEST I
09:00–10:00	Skalkotas Hall	SYMPOSIUM SY47 Patient Advocacy Groups CHAIRS: Bettina Ryll, Uppsala, Sweden 09:00–09:05 Welcome and Introduction Bettina Ryll, Uppsala, Sweden 09:05–09:15 Long-term follow-up of Stage 3 Melanoma patients in Germany Katharina Kaminski, Essen, Germany 09:15–09:25 Addressing gaps in melanoma care: Leveraging biomarkers for equity and better outcomes Samantha Guild, Richmond, USA 09:25–09:35 Access to novel medicines – the WHO Europe Novel Medicines Platform Violeta Astratinei, Amsterdam, The Netherlands 09:35–09:45 Access to advanced molecular testing for additional treatment options in Melanoma – learnings from DRUP-like clinical trials Bettina Ryll, Uppsala, Sweden 09:45–10:00 Questions and discussions

09:00–10:00	M3	SYMPOSIUM SY48 Interdisciplinary tumor board: challenging skin cancer cases II CHAIRS: Petr Arenberger, Prague, Czech Republic Matilda Bylaite-Bucinskiene, Vilnius, Lithuania David Moreno-Ramirez, Seville, Spain 09:00–09:10 Case 1 Petr Arenberger, Prague, Czech Republic 09:12–09:22 Case 2 David Moreno-Ramirez, Seville, Spain 09:24–09:34 Case 3 Monika Arenbergerova, Prague, Czech Republic 09:36–09:46 Case 4 Mirna Situm, Zagreb, Croatia 09:46–09:58 Case 5 Matilda Bylaite-Bucinskiene, Vilnius, Lithuania
10:00–10:30		Break
10:30–11:00	Trianti Hall	KEYNOTE LECTURE KEY06 CHAIR: Ryan Sullivan, Boston, USA Improving outcomes in melanoma beyond the standard use of immune checkpoint blockers Caroline Robert, Paris, France
11:00–11:30	Trianti Hall	KEYNOTE LECTURE KEY07 CHAIR: Brigitte Dréno, Nantes, France The future of non-melanoma skin cancer treatment Chrysalyne Schmults, Boston, USA
11:30–12:30	Trianti Hall	SYMPOSIUM SY49 New devices for... CHAIRS: Giovanni Pellacani, Modena, Italy Julia Welzel, Augsburg, Germany 11:30–11:42 ... Pigmented lesions Giovanni Pellacani, Rome, Italy 11:45–11:57 ... Epithelial tumors Mariano Suppa, Brussels, Belgium 12:00–12:12 ... Mohs' surgery with ex vivo confocal microscopy Javiera Perez, Barcelona, Spain 12:15–12:27 ... AI in imaging Julia Welzel, Augsburg, Germany

11:30–12:30	Banqueting Hall	SYMPOSIUM SY50 Management of adverse events in immuno-oncology CHAIRS: Brigitte Dréno, Nantes, France Elisabeth Livingstone, Essen, Germany 11:30–11:42 Immune-related cardiotoxicity: how to detect, monitor and treat? Carrie Lenneman, Birmingham, USA 11:45–11:57 Difficult to treat colitis: what's next? Elisabeth Livingstone, Essen, Germany 12:00–12:12 Balancing ir-adverse events and benefit of immunotherapy Brigitte Dréno, Nantes, France 12:15–12:27 Get ready for bispecific antibodies and T cells: how to prevent and treat specific adverse events Heather Shaw, London, United Kingdom
11:30–12:30	Mitropoulos Hall	DERMOSCOPY CONTEST II
11:30–12:30	Skalkotas Hall	SYMPOSIUM SY51 Promising agents for PD1-refractory patients CHAIRS: Michael Postow, New York, USA Ana Arance, Barcelona, Spain 11:30–11:42 Efficacy and safety of RP1 combined with nivolumab in patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial Michael K. Wong, Houston, USA 11:45–11:57 Bispecific antibody therapies: Emerging new strategies and learnings from tebentafusp Jessica Hassel, Heidelberg, Germany 12:00–12:12 Can Histone deacetylases (HDAC) inhibitors challenge immune checkpoint resistance in melanoma? Ana Arance, Barcelona, Spain 12:15–12:27 Will antibody drug conjugates have a role in melanoma treatment? Michael Postow, New York, USA

11:30–12:30	M3	SYMPOSIUM SY52 Melanoma – genomics and morphology CHAIRS: Helen Kalirai, Liverpool, United Kingdom David Adams, Cambridge, United Kingdom 11:30–11:42 Translating the genomic architecture and pathology of melanoma into new therapies David Adams, Cambridge, United Kingdom 11:45–11:57 The spatial transcriptomics of leptomeningeal spread in melanoma Inna Smalley, Tampa, USA 12:00–12:12 Classification of the tumour microenvironment and immune therapy response James Wilmott, Sydney, Australia 12:15–12:27 Application of AI to digitised images of uveal melanoma morphology Helen Kalirai, Liverpool, United Kingdom
11:30–12:30		FREE COMMUNICATION V CHAIRS: Lidija Kandolf, Belgrade, Serbia Konstantinos Krasagakis, Athens, Greece
12:30–12:40		POSTER AWARDS Committee: Céleste Lebbé, Paris, France Chrysalyne Schmults, Boston, USA Friedegund Meier, Dresden, Germany Jürgen Becker, Essen, Germany
12:40–13:15		Break
13:15–14:15		SYMPOSIUM SY53 Treatment at the end of the life CHAIRS: Andrea Forschner, Tuebingen, Germany Carola Berking, Erlangen, Germany Sapna Patel, Denver, USA 13:15–13:30 End-of-life therapy of advanced skin cancer: Results of a large multiregistry study Andrea Forschner, Tuebingen, Germany 13:35–13:50 Challenges and evidence-based guidelines of palliative care in Germany Carola Berking, Erlangen, Germany 13:55–14:10 Treatment beyond progression in skin cancer Sapna Patel, Denver, USA

13:15–14:15	Banqueting Hall	SYMPOSIUM SY54 Management of adverse events in targeted therapies CHAIRS: Vincent Sibaud, Toulouse, France Viky Nikolaou, Athens, Greece 13:15–13:27 New insights in epidermal growth factors receptor-related dermatologic toxicities Michela Starrace, Bologna, Italy 13:30–13:42 Management of systemic adverse events of targeted therapies Peter Kölblinger, Salzburg, Austria 13:45–13:57 Management of adverse events caused by hedgehog inhibitors Viky Nikolaou, Athens, Greece 14:00–14:12 New targeted therapies: new dermatological toxicities Vincent Sibaud, Toulouse, France
13:15–14:15	Mitropoulos Hall	SYMPOSIUM SY55 Management of lentigo maligna and acral lentiginous melanomas CHAIRS: Zoe Apalla, Thessaloniki, Greece Yasuhiro Nakamura, Saitama, Japan 13:15–13:27 Surgical management of lentigo maligna Eduardo Nagore, Valencia, Spain 13:30–13:42 The role of topical immunotherapy in the management of lentigo maligna Zoe Apalla, Thessaloniki, Greece 13:45–13:57 Surgical management for acral melanoma: different from non-acral cutaneous melanomas? Takamichi Ito, Fukuoka, Japan 14:00–14:12 Adjuvant immunotherapy of acral melanoma – as good as for other subtypes? Yasuhiro Nakamura, Saitama, Japan
13:15–14:15	Skalkotas Hall	SYMPOSIUM SY56 Immune checkpoint inhibition in immunocompromised patients CHAIRS: Lisa Zimmer, Essen, Germany Elsemeike Plasmeijer, Amsterdam, The Netherlands 13:15–13:30 Immune checkpoint inhibition in patients with hematological malignancy Florentia Dimitriou, Houston, USA 13:35–13:50 Immune checkpoint inhibition in organ transplant patients Lisa Zimmer, Essen, Germany 13:55–14:10 Upcoming research on local immunotherapy Elsemeike Plasmeijer, Amsterdam, The Netherlands

13:15–14:15	N3	SYMPOSIUM SY57 Melanocytic lesions of unknown potential: biology, prognosis, treatment and follow-up CHAIRS: Klaus Griewank, Essen, Germany Francesca Maria Bosisio, Leuven, Belgium 13:15–13:30 Introduction to the concept of atypical melanocytic tumors: a practical approach Francesca Maria Bosisio, Leuven, Belgium 13:35–13:50 Latest in genetics in difficult to classify tumors Hensin Tsao, Boston, USA 13:55–14:10 AI in classifying MELTUMP – Experience so far and potential Klaus Griewank, Essen, Germany
13:15–14:45	N2	SYMPOSIUM SY58 Cutaneous melanoma risk and progression in Mediterranean populations and beyond (MelaNostrum) CHAIR: Maria Teresa Landi, Bethesda, USA 13:15–13:20: Introduction to the MelaNostrum Consortium Maria Teresa Landi, Bethesda, USA 13:20–13:35: Novel susceptibility variants in >3000 familial melanoma cases from Mediterranean countries Kevin Brown, Bethesda, USA 13:35–13:50: Characterization of melanomas in subjects with no common risk factors for the disease Eduardo Nagore, Valencia, Spain 13:50–14:06: A genome-wide association study (GWAS) of >76,000 melanoma cases worldwide Maria Teresa Landi, Bethesda, USA 14:06–14:14: Spatial multi-omics analysis of progression and immunoediting to evaluate individual recurrence risk prediction in stage II cutaneous melanoma Lucia Di Nardo, Rome, Italy 14:14–14:22: Molecular profiling and imaging of paired primary and metastatic melanomas: an ongoing Consortium-based research project Cristina Pellegrini, L'Aquila, Italy 14:22–14:30: A multiparameter liquid biopsy approach allows tracking of melanoma dynamics and early detection of treatment resistance Maria Chiara Scaini, Padova, Italy 14:30–14:45: Discussion

14:15–15:15	Trianti Hall	SYMPOSIUM SY59 Dermoscopy 2: Dermoscopy in melanoma management CHAIRS: Aimilios Lallas, Thessaloniki, Greece Caterina Longo, Reggio Emilia, Italy 14:15–14:27 ... does the age matter? Aimilios Lallas, Thessaloniki, Greece 14:30–14:42 ... does anatomic location matter? Caterina Longo, Reggio Emilia, Italy 14:45–14:57 ... does size matter? Elvira Moscarella, Reggio Emilia, Italy 15:00–15:12 ... does skin color matter? Bengu Nisa Akay, Ankara, Turkey
14:15–15:15	Banqueting Hall	SYMPOSIUM SY60 Actinic keratosis: current treatment and future perspectives CHAIRS: Catherine Harwood, London, United Kingdom Thomas Dirschka, Wuppertal, Germany Aleksandar Sekulic, Phoenix, USA 14:15–14:27 Prognostic factors in actinic keratoses Thomas Dirschka, Wuppertal, Germany 14:30–14:42 Actinic keratoses in immunosuppressed patients Catherine Harwood, London, United Kingdom 14:45–14:57 Modern imaging of actinic skin damage Mariano Suppa, Brussels, Belgium 15:00–15:12 Treatment innovations and pipeline products for actinic keratosis Aleksandar Sekulic, Phoenix, USA
14:15–15:15	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT14 Further Sponsor Detailed Information Page 68–74

14:15–15:15	Skalkotas Hall	SYMPOSIUM SY61 Diagnosis and management of cutaneous T-and B-cell lymphomas CHAIRS: Pablo Ortiz, Madrid, Spain Michael Weichenthal, Kiel, Germany 14:15–14:27 How I manage mycosis fungoides and Sézary syndrome Pablo Ortiz-Romero, Madrid, Spain 14:30–14:42 Itch management in cutaneous T-cell lymphoma Evangelia Papadavid, Athens, Greece 14:45–14:57 Diagnosis and management of primary cutaneous B-cell lymphomas Michael Weichenthal, Kiel, Germany 15:00–15:12 What is new in diagnosis and management of aggressive T-cell lymphomas Julia Scarisbrick, Birmingham, United Kingdom
14:15–15:15	M3	SYMPOSIUM SY62 Interdisciplinary tumor board: challenging skin cancer cases III CHAIRS: Thomas Eigentler, Berlin, Germany Judit Oláh, Szeged, Hungary 14:15–14:25 Leptomeningeal melanomatosis without melanoma Thomas Eigentler, Berlin, Germany 14:27–14:37 Local ablative techniques in the complex management of the difficult-to-treat cutaneous tumours Judit Olah, Szeged, Hungary 14:39–14:49 Difficult-to-treat epithelial tumours on the head and neck region Rolland Gyulai, Szeged, Hungary 14:51–15:01 Skin cancer treatment in pregnancy Marie-Lena Rasch, Tuebingen, Germany 15:03–15:13 Against all odds Georg Weinlich, Innsbruck, Austria
15:15–16:15	Trianti Hall	SYMPOSIUM SY63 Dermoscopy 3: Difficult clinical scenarios CHAIRS: Harald Kittler, Vienna, Austria Aimilios Lallas, Thessaloniki, Greece 15:15–15:27 Young patients with nodular lesions Aimilios Lallas, Thessaloniki, Greece 15:30–15:42 Middle aged patient with melanonychia striata Harald Kittler, Vienna, Austria 15:45–15:57 Old patients with flat pigmented lesions Giuseppe Argenziano, Naples, Italy 16:00–16:12 Patients with genital lesions Betty Lazaridou, Thessaloniki, Greece

15:15–16:15	Banqueting Hall	SYMPOSIUM SY64 Surgery of stage IV melanoma: still needed? CHAIRS: Alberto Wainstein, Belo Horizonte, Brazil Vernon Sondak, Tampa, USA Piotr Rutkowski, Warsaw, Poland 15:15–15:30 When is surgery indicated for stage IV melanoma? Alberto Wainstein, Belo Horizonte, Brazil 15:35–15:50 When and what are the adjuvant therapy indications and regimens for stage IV melanoma? Piotr Rutkowski, Warsaw, Poland 15:55–16:10 Principles of surgery after systemic therapy Vernon Sondak, Tampa, USA
15:15–16:15	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT15 Further Sponsor Detailed Information Page 68–74
15:15–16:15	Skalkotas Hall	SYMPOSIUM SY65 Current primary staging and follow-up recommendations for melanoma patients CHAIRS: Iris Zalaudek, Trieste, Italy Ulrike Leiter-Stöppke, Tuebingen, Germany 15:15–15:30 Primary staging and follow-up in stage I/IIA – less is more? Iris Zalaudek, Trieste, Italy 15:35–15:50 Staging and imaging in stage IIB–III before during and after adjuvant therapy Ulrike Leiter-Stöppke, Tuebingen, Germany 15:55–16:10 Staging and follow-up in stage IV Michael Weichenthal, Kiel, Germany
15:15–16:15	M3	SYMPOSIUM SY66 Genetic susceptibility of melanoma and cancer syndromes CHAIRS: Susana Puig, Barcelona, Spain Irene Stefanaki, Athens, Greece 15:15–15:30 Characterization of genetically enriched melanoma cases in Greece Irene Stefanaki, Athens, Greece 15:35–15:50 Genetic susceptibility to melanoma and deep phenotyping Susana Puig, Barcelona, Spain 15:55–16:10 Other cancer syndromes with skin cancer Anne Zaremba, Essen, Germany
16:15–16:30		FAREWELL & CLOSING REMARKS Alexander Stratigos, Athens, Greece

SATELLITE SYMPOSIA AT A GLANCE

APRIL 3TH–5TH, 2025

Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building	
	09:15–10:15 SATELLITE SYMPOSIUM SAT01 Gold Sponsor		THURSDAY, APRIL 3 TH , 2025
11:45–12:45 SATELLITE SYMPOSIUM SAT02 Regeneron			
	13:45–14:45 SATELLITE SYMPOSIUM SAT03 Bristol Meyer Squibb		
		14:45–15:15 SATELLITE SYMPOSIUM SAT04 Silver Sponsor	
		15:15–15:45 SATELLITE SYMPOSIUM SAT05 Replimune	
		16:15–16:45 SATELLITE SYMPOSIUM SAT06 Almirall	
		16:45–17:45 SATELLITE SYMPOSIUM SAT07 Castle Biosciences	
		08:30–09:30 SATELLITE SYMPOSIUM SAT08 Pierre Fabre	FRIDAY, APRIL 4 TH , 2025
	09:30–10:30 SATELLITE SYMPOSIUM SAT09 Immunocore		
		11:00–12:00 SATELLITE SYMPOSIUM SAT10 SunPharma	
12:00–13:00 SATELLITE SYMPOSIUM SAT11 MSD			
		15:00–16:00 SATELLITE SYMPOSIUM SAT12 SunPharma	
		16:15–17:15 SATELLITE SYMPOSIUM SAT13 Further Sponsor	
		14:15–15:15 SATELLITE SYMPOSIUM SAT14 Further Sponsor	SATURDAY, APRIL 5 TH , 2025
		15:15–16:15 SATELLITE SYMPOSIUM SAT15 Further Sponsor	

SATELLITE SYMPOSIA PROGRAM

THURSDAY, APRIL 3TH, 2025

Banqueting Hall 09:15–10:15
SATELLITE SYMPOSIUM SAT01

To be announced

REGENERON

Trianti Hall 11:45–12:45
SATELLITE SYMPOSIUM SAT02

**New Horizons: Reshaping the Treatment Landscape
of Non-melanoma Skin Cancer**

CHAIR: Alexander Stratigos, Athens, Greece

11:45–12:00 **Welcome and Introduction**
Alexander Stratigos, Athens, Greece

12:00–12:15 **Paving the Way: Paradigm Shifts in the Treatment of
Cutaneous Squamous Cell Carcinoma**
Alexander Stratigos, Athens, Greece

12:15–12:30 **Bridging the Gaps: Addressing Unmet Needs in
Non-melanoma Skin Cancer (Illustrative Cases)**
Alexander Stratigos, Athens, Greece
Paolo Ascierto, Naples, Italy
Reinhard Dummer, Zurich, Switzerland

12:30–12:45 **Audience Q&A and Faculty Discussion**
All



Banqueting Hall 13:45–14:45
SATELLITE SYMPOSIUM SAT03

**Exploring metastatic melanoma therapies:
The value of the patient's perspective**

To be announced

Mitropoulos Hall 14:45–15:15
SATELLITE SYMPOSIUM SAT04

To be announced



Mitropoulos Hall 15:15–15:45

SATELLITE SYMPOSIUM SAT05

Optimizing treatment for skin cancers in immunocompromised patients

CHAIR: Alexander Stratigos, Athens, Greece

15:15–15:17 **Introduction**

Alexander Stratigos, Athens, Greece

15:17–15:25 **Skin cancer risks in the post-transplant setting**

Sandy Kolovou, Athens, Greece

15:25–15:40 **Treatment paradigms for post-transplantation cutaneous malignancies**

Michael Migden, Houston, USA

15:40–15:45 **Discussion, Q&A and Conclusions**

Alexander Stratigos, Athens, Greece



Mitropoulos Hall 16:15–16:45

SATELLITE SYMPOSIUM SAT06

Actinic keratosis and beyond...

CHAIR: Markus Heppt, Erlangen, Germany

Marco Ardigo, Rozzano, Italy

16:15–16:30 **Patient understanding is first...**

Markus Heppt, Erlangen, Germany

16:30–16:45 **... Lesion characterization is key**

Marco Ardigo, Rozzano, Italy



Mitropoulos Hall 16:45–17:45

SATELLITE SYMPOSIUM SAT07

To be announced

SATELLITE SYMPOSIA PROGRAM

FRIDAY, APRIL 4TH, 2025



Mitropoulos Hall 08:30–09:30

SATELLITE SYMPOSIUM SAT08

**Optimizing Actinic Keratosis Treatment:
Expert Tips and Proven Strategies with 4% 5-FU**

CHAIR: Aimilios Lallas, Thessaloniki, Greece

08:30–08:32 **Introduction**

Aimilios Lallas, Thessaloniki, Greece

08:32–08:47 **Management of Actinic keratosis:**

Positioning of the 5-FU in the European guidelines

Markus Heppt, Erlangen, Germany

08:47–09:02 **Optimizing Actinic Keratosis Treatment with 4% 5-Fluorouracil:
Key Findings from the Dose-Ranging Study**

Claas Ulrich, Berlin, Germany

09:02–09:07 **Transition**

Aimilios Lallas, Thessaloniki, Greece

09:07–09:22 **Expert Consensus on Actinic Keratosis Management:
Insights from the Delphi Study**

Giuseppe Argenziano, Naples, Italy

09:22–09:27 **Q&A Session**

Claas Ulrich, Berlin, Germany

Giuseppe Argenziano, Naples, Italy

09:27–09:30 **Closing remarks**

Aimilios Lallas, Thessaloniki, Greece

IMMUNOCORE**Banqueting Hall 09:30–10:30****SATELLITE SYMPOSIUM SAT09****Evolving ImmTAC therapy in melanoma**09:30–09:35 **Welcome and Introduction**
Chair09:35–09:45 **Development of the ImmTAC platform – a translational perspective**09:45–10:00 **ImmTAC in the clinic – lessons learnt from metastatic Uveal Melanoma (mUM)**10:00–10:15 **ImmTAC in melanoma – where do we go next ?**10:15–10:30 **Panel Discussion****Mitropoulos Hall 11:00–12:00****SATELLITE SYMPOSIUM SAT10**

To be announced

**Trianti Hall 12:00–13:00****SATELLITE SYMPOSIUM SAT11****Transforming early-stage melanoma and cutaneous SCC care:
New hope through innovative therapies****Mitropoulos Hall 15:00–16:00****SATELLITE SYMPOSIUM SAT12****The neoadjuvant approach in resectable stage III melanoma in 2025:
current evidence**

Mitropoulos Hall 16:15–17:15**SATELLITE SYMPOSIUM SAT13**To be announced

SATELLITE SYMPOSIA PROGRAM


SATURDAY, APRIL 5TH, 2025

Mitropoulos Hall 14:15–15:15
SATELLITE SYMPOSIUM SAT14

To be announced

Mitropoulos Hall 15:15–16:15
SATELLITE SYMPOSIUM SAT15

To be announced

 **11TH WORLD CONGRESS
OF MELANOMA**
IN CONJUNCTION WITH
21ST EADO CONGRESS



Melanoma
World Society
MWS

SPONSORS AND EXHIBITORS



SPONSORS AND EXHIBITORS

PLATINUM SPONSOR

REGENERON



GOLD SPONSOR

IMMUNOCORE

SILVER SPONSOR



BRONZE SPONSOR



FURTHER SPONSORS/EXHIBITORS



Dermavision Solutions



Integra



New Horizons: Reshaping the Treatment Landscape of Non-Melanoma Skin Cancer

Thursday, 3 April 2025 | 11:45–12:45 EET

The Alexandra Trianti Hall,
Megaron Athens International Conference Centre



Alexander J. Stratigos
Chair



Reinhard Dummer



Paolo A. Ascierto

**You are invited to attend
the Regeneron-sponsored
satellite symposium, featuring:**

- The evolving treatment landscape and latest advancements in immunotherapy for NMSC
- Illustrative cases, focusing on unmet needs in the treatment of CSCC and BCC

Every time we care for a single person, we make the whole world better.



New ways to care.

At Pierre Fabre Laboratories, we have a passion for addressing clinical challenges through innovative solutions, keeping patients at the core of our efforts.

The fight against cancer is our main priority in medical care.


We take a holistic approach to cancer care focusing not only on treatment, but also prevention and support.



Our mission is to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies

The RPx platform is intended to ignite a local and systemic response to cancer

We imagine a world where cancer is a curable disease





2025 in Hamburg

15th European Post-Chicago Melanoma/Skin Cancer Meeting

**Hamburg | Germany
Radisson Blu Hotel**

**June
26th–27th
2025**

**SAVE
THE
DATE**

**SAVE
THE
DATE**

13th EUROPEAN SCHOOL OF DERMATO-ONCOLOGY

AN INTERACTIVE COURSE MEETING

JUNE 27TH-28TH, 2025

RADISSON BLU HOTEL
HAMBURG, GERMANY



Course Directors
Claus Garbe, Tuebingen, Germany
Axel Hauschild, Kiel, Germany

Apply now for EADO Certification 2025



EADO Certification: Medical Tumour Therapy in Dermato-Oncology

June 28, 2025

**Radisson Blu Hotel
Hamburg, Germany**

APPLICATION DEADLINE MAY 15, 2025

**VISIT
EADO.ORG**



